: Received: 12 February 2021 / Approved: 15 February 2021 / Online: 15 February 2021 (14:55:01 CET)
: Received: 18 February 2021 / Approved: 22 February 2021 / Online: 22 February 2021 (07:51:33 CET)
Okamoto, S.; Shiga, T.; Tamaki, N. Clinical Perspectives of Theranostics. Molecules2021, 26, 2232.
Okamoto, S.; Shiga, T.; Tamaki, N. Clinical Perspectives of Theranostics. Molecules 2021, 26, 2232.
Theranostics covers combination of diagnostic and therapeutic techniques for various cancers throughout body using suitable drug combination. This review covers well-known treatment of thyroid cancer and pheochromocytoma with I-131 compounds and also new radiopharmaceuticals for prostatic cancer and pancreatic cancer. Of particular, new trends toward patient outcome has been focused. A recent clinical study highlighted the ability of alpha-radiotherapy with high LET to overcome treatment resistance to beta--particle therapy. The theranostics will become an ever-increasing part of clinical nuclear medicine these days.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.